Gland Pharma Reports Strong Q2 FY26 Results with 6% Revenue and 12% PAT Growth YoY

Gland Pharma Limited announced its consolidated financial results for the second quarter ended September 30, 2025 (Q2 FY26): * Consolidated Financial Performance (Q2 FY26 vs Q2 FY25): * Revenue from operations increased by 6% year-on-year to ₹14,869 million. * Gross Profit rose by 12% to ₹9,331 million, with a margin of 63%. * EBITDA increased by 6% to ₹3,139 million, maintaining a margin of 21%. * Adjusted EBITDA grew by 13% to ₹3,355 million, with a margin of 23%. * Profit After Tax (PAT) was up by 12% to ₹1,837 million, achieving a margin of 12%. * Half-Yearly Performance (6M FY26 vs 6M FY25): * Revenue grew by 7%. * PAT surged by 30%. * Management Commentary: * Mr. Srinivas Sadu, Executive Chairman, highlighted a strong first half of FY26 with 7% revenue growth and 30% PAT increase, anticipating stronger momentum in the second half driven by new launches and Cenexi’s recovery. He also mentioned continued investments in CDMO expansion, capacity enhancement, and complex injectables pipeline. * Mr. Shyamakant Giri, CEO, noted the core business's profitable growth and margin expansion. He reported year-over-year improvement in consolidated business for Q2 FY26, with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi. He expects robust growth in upcoming quarters. * Key Business Highlights: * R&D expenses increased to ₹614 million in Q2 FY26 (5.8% of revenue). * Seven new molecules, including Daptomycin-RTU and Sumatriptan, were launched in the USA. * Six ANDAs were filed and five approved in Q2 FY26, bringing the total U.S. filings to 378 (329 approved, 49 pending). * Six complex injectable products have been launched, with three more in line for approval. * Fifteen products are in co-development, with commercialization expected from FY28. * The company has filed 20 Ready-to-Use (RTU) infusion bag products, with 14 approvals and 10 under development, targeting a US market opportunity of approximately $659 million (₹5,490 crore). * GLP-1/Pen/cartridge capacity is being aggressively increased from ~40 million to 140 million units. * Cenexi Financial Performance (Q2 FY26): * Revenues were up by 21% year-on-year (in Euro terms) despite a planned shutdown. * The Fontenay Facility completed infrastructure upgrades, renewed its GMP certificate through end of CY2026, and resumed production with improved order shipments. * Hérouville Facility activities are on track, with ramp-up of an inactivated vaccine and a sterile ophthalmic gel. * Qualification of two new lyophilizers at Braine-L’Alleud & Osny is expected by the end of 2025. * Earnings Call: An earnings call to discuss the results is scheduled for November 3, 2025, at 6:30 PM (IST).